BO1 fundamentals
An in-depth look to BIOCRYST PHARMACTL operating, investing, and financing activities
BO1 free cash flow for Q1 24 is -48.99 M CHF. For 2023, BO1 free cash flow was -81.93 M CHF and operating cash flow was -80.1 M CHF.
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: CHF
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
TTM